WuXi Apptec

Historical price data

WuXi AppTec has established itself as the world's preeminent integrated CRDMO, enabling pharmaceutical innovation through its comprehensive, non-dilutive service platform spanning chemistry, biology, and testing. Founded in 2000, the company has grown into a $345+ billion market cap powerhouse by providing critical R&D and manufacturing infrastructure to the global biopharma industry, from startups to multinationals. Its strategy centers on vertical integration, global scale, and technological depth, which has driven consistent double-digit growth and a formidable competitive moat.

An integrated, end-to-end Contract Research, Development, and Manufacturing Organization (CRDMO) platform combining WuXi Chemistry (small molecule CRDMO), WuXi Biology (discovery biology), and WuXi Testing (preclinical and testing services) to enable drug development from discovery to commercial manufacturing.

WuXi AppTec's main competitors include integrated service providers like LabCorp's Covance and Charles River Labs, large CMOs like Lonza and Catalent, and numerous niche players. Its key advantages are unparalleled scale in China, true end-to-end service integration, and a 'one-stop-shop' model that creates high switching costs for clients.